Tagitanlimab

Modify Date: 2024-04-11 11:13:00

Tagitanlimab structure	Common Name	Tagitanlimab
	CAS Number	2417649-97-7	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Tagitanlimab

Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC)[1][2].

Name	Tagitanlimab

Description	Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC)[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1
References	[1]. Lu S, et al. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. Oncologist. 2019 Feb;24(Suppl 1):S21-S30. [2]. Kaplon H, et al. Antibodies to watch in 2023. MAbs. 2023 Jan-Dec;15(1):2153410.

Description

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1

References

[1]. Lu S, et al. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. Oncologist. 2019 Feb;24(Suppl 1):S21-S30.

[2]. Kaplon H, et al. Antibodies to watch in 2023. MAbs. 2023 Jan-Dec;15(1):2153410.

No Any Chemical & Physical Properties